Momenta Phamaceuticals, Inc. (MNTA) Misses Q2 EPS by 2c; Affirms Outlook

August 2, 2012 8:28 AM EDT
Momenta Phamaceuticals, Inc. (NASDAQ: MNTA) reported Q2 EPS of ($0.20), $0.02 worse than the analyst estimate of ($0.18). Revenue for the quarter came in at $21.9 million versus the consensus estimate of $18.99 million.

Momenta Phamaceuticals, Inc. reaffirmed FY2012 guidance.

For earnings history and earnings-related data on Momenta Phamaceuticals, Inc. (MNTA) click here.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings, Guidance

Related Entities

Earnings